Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 200

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 200
---
 this proxy statement/prospectus, unless defined below. As used in this unaudited pro forma condensed combined financial information, “Liminatus” refers to Liminatus Pharma, LLC, a company incorporated under the laws of Delaware, and “Iris” refers to Iris Acquisition Corp (formerly Tribe Capital Growth Corp I) prior to the Business Combination.

The unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X and presents the combination of the historical financial information of Iris and Liminatus, adjusted to give effect to the Business Combination and the other events contemplated by the Business Combination Agreement. Unless otherwise indicated or the context otherwise requires, references to the “Combined Company” refer to Iris Parent Holding Corp. (“ParentCo”), a Delaware company, and its consolidated subsidiaries after giving effect to the Business Combination.

The unaudited pro forma combined balance sheet as of September 30, 2024 combines the historical balance sheets of Iris and Liminatus on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on September 30, 2024. The unaudited pro forma combined statement of operations for the nine months ended September 30, 2024 and year ended December 31, 2023, combines the historical statements of operations of Iris and Liminatus on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on January 1, 2023, the beginning of the earliest period presented.

The unaudited pro forma combined balance sheet as of September 30, 2024 and unaudited pro forma combined statement of operations for the nine months ended September 30, 2024 has been derived from and should be read in conjunction with the following:

•

the historical unaudited financial statements of Iris as of September 30, 2024 and for the nine months ended September 30, 2024 and the related notes, which are included in Iris’s Quarterly Report on Form 10-Q filed with the SEC on November 27, 2024 (the “Iris September 2024 10-Q”), which are included elsewhere in this proxy statement/prospectus; and

•

the historical unaudited financial statements of Liminatus as of September 30, 2024 and for the nine months ended September 30, 2024 and the related notes, which are included elsewhere in this proxy statement